Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Tetrahydrobiopterin (BH4) analog for phenylketonuria

Sapropterin Dihydrochloride

Kuvan

Dosage form
Tablet
Available strengths
100 mg tablets; 100 mg and 500 mg sachets (powder for oral solution)
Drug class
Tetrahydrobiopterin (BH4) analog for phenylketonuria
Common brand
Kuvan

Clinical overview. Sapropterin dihydrochloride (Kuvan) is a synthetic form of tetrahydrobiopterin (BH4) used, along with a phenylalanine-restricted diet, to lower blood phenylalanine levels in people with BH4-responsive phenylketonuria (PKU). It is taken once daily with food as a tablet or dissolved powder, and response must be confirmed with a trial period of blood phenylalanine monitoring. Side effects are generally mild, though allergic reactions, stomach irritation, and low blood phenylalanine levels in young children have been reported.

Indication

Common therapeutic uses

  • Sapropterin dihydrochloride is used, together with a phenylalanine-restricted diet, to lower blood phenylalanine levels in patients with hyperphenylalaninemia due to BH4-responsive phenylketonuria (PKU).
  • Not all patients with PKU respond to sapropterin; a therapeutic trial period is needed to determine whether an individual patient responds.

Pregnancy

Risk assessment and monitoring considerations

  • There are no adequate, well-controlled studies of sapropterin in pregnant women, though available pregnancy registry data have not shown an increased risk of major birth defects.
  • Poorly controlled blood phenylalanine levels during pregnancy in women with PKU are themselves teratogenic and can cause serious birth defects, known as maternal PKU syndrome.
  • Strict dietary control of phenylalanine before and during pregnancy is the first-choice treatment; sapropterin should be used only if diet alone does not adequately control blood phenylalanine.
  • Sapropterin has not been studied for use during labour and delivery and is not recommended for this purpose.

Breastfeeding

Infant exposure considerations

  • It is not known whether sapropterin passes into human breast milk.
  • Because of the potential for serious reactions in a nursing infant, and evidence of tumour development in an animal carcinogenicity study, sapropterin should not be used while breastfeeding.

Geriatrics

Dosing and tolerability considerations

  • Clinical studies of sapropterin did not include patients aged 50 years and older.
  • It is not known whether older patients respond differently than younger patients.

Pediatrics

Use in children and adolescents

  • Sapropterin is authorized for use in patients 1 month of age and older with PKU.
  • Safety and efficacy have not been established in infants younger than 1 month.
  • Children younger than 7 years, including infants, have a higher risk of developing low blood phenylalanine levels during treatment and need closer monitoring.
  • Prolonged low blood phenylalanine and tyrosine levels during infancy have been linked to impaired neurodevelopment.

Dosage & Administration

Practical dosing and administration

  • The recommended starting dose of sapropterin is 10 mg/kg taken once daily.
  • Blood phenylalanine levels are checked after the first week and periodically over the first month to determine response.
  • If blood phenylalanine has not decreased after a month at the starting dose, the dose may be increased weekly up to a maximum of 20 mg/kg/day.
  • Patients whose blood phenylalanine does not improve after a month at the maximum dose are considered non-responders and treatment should be stopped.
  • Once a response is confirmed, the dose is adjusted within a range of 5 to 20 mg/kg/day based on ongoing blood phenylalanine monitoring.
  • Tablets can be swallowed whole or dissolved in water or apple juice; the powder for oral solution is dissolved in water or apple juice; both should be consumed within 15 minutes of preparation.
  • Sapropterin should be taken with a meal, since food increases how much of the drug is absorbed.
  • A missed dose should be taken as soon as possible, but two doses should not be taken on the same day.
  • No dedicated dosing studies exist for patients with kidney or liver impairment; such patients should be monitored carefully during treatment.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Reported overdoses of sapropterin have caused mild, temporary headache and dizziness that resolved without treatment.
  • One reported pediatric overdose caused hyperactivity that resolved once the dose was reduced back to the recommended level.
  • Upper abdominal pain has been reported after doses above the recommended maximum.
  • A single supratherapeutic dose in a study caused a dose-related shortening of the QT interval on ECG, along with abdominal pain and dizziness in some subjects.
  • Overdose should be treated based on the specific symptoms present.

Common side effects

Frequently reported tolerability concerns

  • Headache may occur.
  • Diarrhea may occur.
  • Abdominal pain may occur.
  • Upper respiratory tract infection may occur.
  • Throat pain may occur.
  • Vomiting may occur.
  • Nausea may occur.
  • Low blood phenylalanine levels (hypophenylalaninemia) may occur, especially in young children.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Gastritis and esophagitis have been reported and, if untreated, can lead to complications such as ulcers, strictures, or bleeding.
  • Hypersensitivity reactions, including anaphylaxis, have occurred; signs include wheezing, difficulty breathing, coughing, low blood pressure, flushing, nausea, and rash.
  • Seizures and worsening of existing seizure disorders have been reported.
  • Hyperactivity has been reported, particularly with doses above the recommended maximum.
  • Prolonged low blood phenylalanine in young children may affect neurological development.
  • Seek urgent medical attention for signs of a severe allergic reaction, chest or throat tightness, difficulty breathing, or a new or worsening seizure.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients taking medicines that cause blood vessel widening, such as nitrates or PDE-5 inhibitors (e.g., sildenafil), since the combination may lower blood pressure further.
  • Use with caution in patients taking medicines that affect folate metabolism, such as methotrexate or trimethoprim, since these can reduce sapropterin's effectiveness.
  • Use with caution in patients taking levodopa, since seizures, agitation, or irritability have been reported with concurrent use.
  • Use with caution in patients with liver impairment, since this population has not been studied and liver damage can affect phenylalanine metabolism.
  • Use with caution in patients with kidney impairment, since this population has not been studied.
  • Use with caution in patients with a history of seizures, since exacerbation of seizures has been reported.
  • Use with caution in young children, who are at higher risk for low blood phenylalanine levels requiring frequent monitoring.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to sapropterin dihydrochloride or to any ingredient in the tablet, powder, or container.

Drug interactions

Clinically relevant combinations

  • Medicines that cause vasodilation, including nitrates, sildenafil, vardenafil, tadalafil, and minoxidil, may have an additive blood-pressure-lowering effect when combined with sapropterin.
  • Methotrexate, trimethoprim, and other drugs that affect folate metabolism may reduce sapropterin's effectiveness by lowering BH4 levels.
  • Levodopa combined with sapropterin has been associated with seizures, worsened seizures, over-stimulation, or irritability in patients with underlying neurologic conditions.
  • Sapropterin may increase blood levels of drugs that are substrates of the BCRP transporter, such as rosuvastatin.
  • A single therapeutic dose of sapropterin did not affect the pharmacokinetics of digoxin in a clinical study.

Food interactions

Meal-related administration

  • Sapropterin should be taken with a meal, since a high-fat, high-calorie meal increases its absorption substantially; taking it on an empty stomach can reduce how well it works.

Time of administration

Practical scheduling

  • Sapropterin is taken once daily with a meal, ideally at about the same time each day, to help maintain consistent absorption.

Storage

Product handling

  • Store sapropterin tablets at room temperature (20-25°C, with excursions permitted between 15-30°C) and protect them from moisture.
  • Store the powder for oral solution at room temperature (15-30°C) and protect it from moisture.

Patient take-away

Key counselling points for a quick closing summary

  • Sapropterin, combined with a phenylalanine-restricted diet, helps lower blood phenylalanine levels in people with BH4-responsive PKU, but it does not replace dietary management.
  • Take sapropterin with a meal every day and keep up with your prescribed low-phenylalanine diet.
  • Regular blood tests are needed to check your phenylalanine levels and adjust your dose or diet as needed.
  • Contact your healthcare provider promptly if you notice stomach pain, signs of an allergic reaction, or a new seizure.

References

Source material and product information

  1. Health Canada Product Monograph — Sapropterin Dihydrochloride

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.